Abstracts tagged "Hyaluronan"

Abstract Number: 1203 • ACR Convergence 2024
My Shoulder Hurts, What Should I Do? A Systematic Review and Bayesian Network Meta-analysis of Different Injectables in Glenohumeral Osteoarthritis
Mohamed Abdelsalam¹, Mona Sajed², Aya Alsaeed³, Heba Abdelrahman⁴, roaa Rafat⁵, Mohamed Tarek⁶ and Asmaa al-Najjar⁷, ¹Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, ²Faculty of Pharmacy - Al-Azhar university for girls, Mansoura, Ad Daqahliyah, Egypt, ³Faculty of medicine - Mansoura university, Mansoura, Ad Daqahliyah, Egypt, ⁴Faculty of medicine - Mansora university, Mansoura, Ad Daqahliyah, Egypt, ⁵Faculty of medicine, Ahfad University for Women, Khartoum, Sudan, Cairo, Egypt, ⁶Faculty of medicine - Al-Azhar university Cairo branch, Cairo, Egypt, ⁷Faculty of medicine - Al-Azhar university in Gaza, Gaza, Palestinian Territories
Background/Purpose: Glenohumeral Osteoarthritis (GH OA) significantly impacts joint function and quality of life. Various intraarticular injectable treatments, including hyaluronic acid (HA), corticosteroids (GCs), platelet-rich plasma…
Abstract Number: 0787 • ACR Convergence 2024
Efficacy of Intra-Articular Hyaluronic Acid Injection for Nonsurgical Management of Carpometacarpal Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Mohamed Abdelsalam¹, omnia Samy² and Asmaa al-Najjar³, ¹Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, ²Faculty of medicine - Zagazig university, Al Zagazig, Egypt, ³Faculty of medicine - Al-Azhar university in Gaza, Gaza, Palestinian Territories
Background/Purpose: Carpometacarpal osteoarthritis (CMC OA) is a painful condition affecting 21% of hand OA patients. Various treatment modalities have been explored to reduce pain and…
Abstract Number: 1840 • ACR Convergence 2023
Value of Various Intra-Articular Injections for Knee Osteoarthritis Management
Hanna Mass¹, Jamie Collins¹, david Hunter², Catherine Yang¹, Morgan Jones¹, Stephen Messier³, Tuhina Neogi⁴, A. David Paltiel⁵, Jeffrey Katz¹ and Elena Losina⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, ³Wake Forest University, Winston-Salem, NC, ⁴Boston University School of Medicine, Boston, MA, ⁵Yale School of Public health, New Haven, CT, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Intra-articular injections (IAI) are commonly used to relieve pain and delay total knee replacement (TKR) in persons with knee OA. Despite higher costs and…
Abstract Number: 0580 • ACR Convergence 2020
Risk of Severe Acute Localized Reactions for Different Intra-Articular Hyaluronic Acid Knee Injections in a Real World Setting
Kevin Ong¹, Jack Farr², Louis McIntyre³, Andrew Gudeman², Iain Murray⁴, Charles Hummer⁵, Wilson Ngai⁶, Heather Good⁷, Edmund Lau⁸ and Roy Altman⁹, ¹Exponent, Philadelphia, ²Indiana University Department of Orthopaedic Surgery, Indianapolis, ³US Orthopedics, Tarrytown, ⁴Department of Orthopaedics, The University of Edinburgh, Edinburgh, United Kingdom, ⁵Premier Orthopaedics and Sports Medicine, Glen Mills, ⁶Sanofi US, Bridgewater, ⁷Sanofi US, Bridgewater, FL, ⁸Exponent, Menlo Park, ⁹David Geffen School of Medicine, University of California, Agua Dulce, CA
Background/Purpose: Case reports of severe acute localized reactions (SALR) following intra-articular (IA) hyaluronic acid (HA) injections for knee osteoarthritis (OA) have been described. These have…
Abstract Number: 1652 • ACR Convergence 2020
Progression of Knee OA with Use of Intra-articular Corticosteroids (CS) vs Hyaluronic Acid (HA)
Justin Bucci¹, Xiaoyang Chen¹, James Torner², Michael Nevitt³, Cora Lewis⁴ and David Felson⁵, ¹Boston University, Boston, MA, ²University of Iowa, Iowa City, IA, ³University of California, San Francisco, Orinda, CA, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵Boston University School of Medicine, Boston, MA
Background/Purpose: Recent studies have questioned whether CS injections (CSI), a popular treatment recommended by guidelines, hasten progression of knee OA. A recent cohort study suggested…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].